Daiichi Sankyo Korea’s 'Lixiana (edoxaban)' continues to dominate the market for Direct Oral Anti-Coagulant (DOAC).

BMS’s 'Eliquis (apixaban)' sales have recently experienced a slowdown, and Bayer’s 'Xarelto (rivaroxaban)' prescription performance significantly dropped after the generic launch. The sales of Xarelto generic nearly chased the original product three years after its launch.

The pharmaceutical industry eyes on the substance expiry of Eliquis this September. Eliquis generics that withdrew from the market after the Supreme Court’s ruling last 2021 may re-enter the market around the time of patent expiry, and a significant shift in the market is expected.